J9179 HCPCS Level II code: Injection, eribulin mesylate, 0.1 mg
J9179 is the HCPCS code for “Injection, eribulin mesylate, 0.1 mg” in CMS’s October 2026 release, in effect from Oct 1, 2026.
Official description
J9179Injection, eribulin mesylate, 0.1 mg
Short description: Eribulin mesylate injection
HCPCS · United States
Medicare details
The indicators CMS publishes with J9179 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Drugs
- ASC
- Approved for ambulatory surgical centers
- Type of service
- Medical care; Lump sum purchase of DME, prosthetics, orthotics
- BETOS category
- Chemotherapy
- Added
- Jan 1, 2012
Where J9179 sits
- 1J codesDrugs administered other than orally
- 2Active code J9179Injection, eribulin mesylate, 0.1 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
What does HCPCS code J9179 mean?
J9179 is the HCPCS code for “Injection, eribulin mesylate, 0.1 mg” in CMS’s HCPCS Level II October 2026 release.
Does Medicare cover J9179?
CMS lists J9179’s Medicare coverage as “Carrier judgment” and its pricing as “Drugs”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside J9179
All J codesJ9173Injection, durvalumab, 10 mgJ9174Injection, docetaxel (beizray), 1 mgJ9175Injection, elliotts' b solution, 1 mlJ9176Injection, elotuzumab, 1 mgJ9177Injection, enfortumab vedotin-ejfv, 0.25 mgJ9178Injection, epirubicin hcl, 2 mgJ9181Injection, etoposide, 10 mgJ9183Gemcitabine intravesical system, 225 mgJ9184Injection, gemcitabine hydrochloride (avyxa), 200 mgJ9185Injection, fludarabine phosphate, 50 mgJ9186Injection, etoposide (avyxa), 1 mgJ9187Injection, etoposide, 1 mg